Shanghai Shyndec Pharmaceutical Co Ltd - Asset Resilience Ratio
Shanghai Shyndec Pharmaceutical Co Ltd (600420) has an Asset Resilience Ratio of 8.99% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Shanghai Shyndec Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Shanghai Shyndec Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 600420 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Shyndec Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shanghai Shyndec Pharmaceutical Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.77 Billion | 8.99% |
| Total Liquid Assets | CN¥1.77 Billion | 8.99% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Shyndec Pharmaceutical Co Ltd maintains only 8.99% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Shyndec Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Shyndec Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Shanghai Shyndec Pharmaceutical Co Ltd (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Shyndec Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.17% | CN¥1.43 Billion ≈ $209.41 Million |
CN¥19.96 Billion ≈ $2.92 Billion |
+6.97pp |
| 2018-12-31 | 0.20% | CN¥33.00 Million ≈ $4.83 Million |
CN¥16.46 Billion ≈ $2.41 Billion |
+0.07pp |
| 2017-12-31 | 0.13% | CN¥20.00 Million ≈ $2.93 Million |
CN¥15.17 Billion ≈ $2.22 Billion |
-0.40pp |
| 2016-12-31 | 0.53% | CN¥80.00 Million ≈ $11.71 Million |
CN¥15.02 Billion ≈ $2.20 Billion |
+0.29pp |
| 2015-12-31 | 0.24% | CN¥10.00 Million ≈ $1.46 Million |
CN¥4.14 Billion ≈ $605.43 Million |
+0.19pp |
| 2007-12-31 | 0.05% | CN¥371.52K ≈ $54.37K |
CN¥713.86 Million ≈ $104.46 Million |
-0.04pp |
| 2004-12-31 | 0.09% | CN¥470.44K ≈ $68.84K |
CN¥516.19 Million ≈ $75.54 Million |
-- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate… Read more